Last update July 17, 2023

Tecovirimat

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Tecovirimat is an antiviral that inhibits the orthopoxvirus VP37 coat protein. It can be used to treat smallpox (in case of an outbreak), monkeypox, and cowpox, and to treat complications due to vaccinia virus replication after smallpox vaccination. Oral administration in 2 daily doses.

At the date of the last update we did not find any published data on its excretion in breast milk.

Its very wide volume of distribution make it highly unlikely that significant quantities will pass into breast milk.

Its side effects are rare and mild. (Siga 2021 y 2020)

Authorized use from 3 kg of weight (DrugBank acces Jul 2023). A 28-month-old boy was treated for 14 days with this drug without side effects. (Vora 2008 )

In severe cases, administration of tecovirimat during lactation should be considered. (CDC 2023)


See below the information of this related product:

Alternatives

We do not have alternatives for Tecovirimat.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Tecovirimat in other languages or writings:

Group

Tecovirimat belongs to this group or family:

Tradenames

Main tradenames from several countries containing Tecovirimat in its composition:

Pharmacokinetics

Variable Value Unit
Molecular weight 376 daltons
Protein Binding 77 - 82 %
VD 5.5 - 14.7 l/Kg
pKa 9.15 -
Tmax 6 hours
19 - 21 hours

References

  1. CDC Centers for Diseases Control. Guidance for Tecovirimat Use. Clinical guidance. 2023 Consulted on July 17, 2023 Full text (link to original source)
  2. Rizk JG, Lippi G, Henry BM, Forthal DN, Rizk Y. Prevention and Treatment of Monkeypox. Drugs. 2022 Jun 28. Consulted on July 13, 2022 Abstract Full text (link to original source)
  3. Gaeta F, De Caro F, Franci G, Pagliano P, Vajro P, Mandato C. Monkeypox Infection 2022: An Updated Narrative Review Focusing on the Neonatal and Pediatric Population. Children (Basel). 2022 Nov 26;9(12). pii: 1832. Abstract Full text (link to original source)
  4. Siga. Tecovirimat. Drug Summary. 2021 Full text (in our servers)
  5. Siga. Tecovirimat. Ficha técnica. 2020 Full text (in our servers)
  6. Vora S, Damon I, Fulginiti V, Weber SG, Kahana M, Stein SL, Gerber SI, Garcia-Houchins S, Lederman E, Hruby D, Collins L, Scott D, Thompson K, Barson JV, Regnery R, Hughes C, Daum RS, Li Y, Zhao H, Smith S, Braden Z, Karem K, et al. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis. 2008 May 15;46(10):1555-61. Abstract

Total visits

925

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM